A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors

被引：0
|
作者：
Shigehisa Kitano
Yutaka Fujiwara
Toshio Shimizu
Satoru Iwasa
Kan Yonemori
Shunsuke Kondo
Akihiko Shimomura
Takafumi Koyama
Takahiro Ebata
Hiroki Ikezawa
Nozomi Hayata
Yukinori Minoshima
Takuma Miura
Tomoki Kubota
Noboru Yamamoto
机构：
[1] National Cancer Center Hospital,Department of Experimental Therapeutics
[2] The Cancer Institute Hospital of JFCR,Department of Advanced Medical Development
[3] Aichi Cancer Center,Department of Thoracic Oncology
[4] National Center for Global Health and Medicine,Department of Breast and Medical Oncology
[5] Eisai Co.,Clinical Data Science Department
[6] Ltd,Clinical Pharmacology Science Department
[7] Eisai Co.,Japan and Asia Clinical Development Department
[8] Ltd,undefined
[9] Tsukuba Research Laboratories,undefined
[10] Eisai Co.,undefined
[11] Ltd,undefined
[12] Eisai Co.,undefined
[13] Ltd,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2022年 / 90卷
关键词：
Biomarkers; Lenvatinib; Pembrolizumab; Pharmacokinetics; Toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：523 / 529
页数：6
相关论文
共 50 条
  • [41] Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab
    Makker, Vicky
    Taylor, Matthew H.
    Oaknin, Ana
    Casado Herraez, Antonio
    Orlowski, Robert
    Dutta, Lea
    Ren, Min
    Zale, Melissa
    O'Malley, David M.
    ONCOLOGIST, 2021, 26 (09): : E1599 - E1608
  • [42] Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab
    Colombo, Nicoletta
    Lorusso, Domenica
    Monk, Bradley J.
    Slomovitz, Brian
    Hasegawa, Kosei
    Nogueira-Rodrigues, Angelica
    Zale, Melissa
    Okpara, Chinyere E.
    Barresi, Gianmaria
    McKenzie, Jodi
    Makker, Vicky
    ONCOLOGIST, 2024, 29 (01): : 25 - 35
  • [43] A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors
    Lakhani, Nehal J.
    Burris III, Howard
    Miller Jr, Wilson H.
    Huang, Mo
    Chen, Lin-Chi
    Siu, Lillian L.
    INVESTIGATIONAL NEW DRUGS, 2024, : 581 - 589
  • [44] Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study
    Munster, Pamela
    Iannotti, Nicholas
    Cho, Daniel C.
    Kirkwood, John M.
    Villaruz, Liza C.
    Gibney, Geoffrey T.
    Hodi, F. Stephen
    Mettu, Niharika B.
    Jones, Mark
    Bowman, Jill
    Smith, Michael
    Lakshminarayanan, Mani
    O'Day, Steven
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (12): : 2572 - 2584
  • [45] A phase I study of resminostat in Japanese patients with advanced solid tumors
    Satoru Kitazono
    Yutaka Fujiwara
    Shinji Nakamichi
    Hidenori Mizugaki
    Hiroshi Nokihara
    Noboru Yamamoto
    Yasuhide Yamada
    Eri Inukai
    Osamu Nakamura
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 1155 - 1161
  • [46] A phase 1 study of ramucirumab in Japanese patients with advanced solid tumors
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Yamada, Yasuhide
    Honda, Kazunori
    Asahina, Hajime
    Tamura, Yosuke
    Hozak, Rebecca R.
    Gao, Ling
    Suzukawa, Kazumi
    Enatsu, Sotaro
    Tamura, Tomohide
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (04) : 298 - 305
  • [47] Phase I study of olaratumab in Japanese patients with advanced solid tumors
    Doi, Toshihiko
    Ma, Yan
    Dontabhaktuni, Aruna
    Nippgen, Cornelia
    Nippgen, Johannes
    Ohtsu, Atsushi
    CANCER SCIENCE, 2014, 105 (07) : 862 - 869
  • [48] A phase 1 study of niraparib in Japanese patients with advanced solid tumors
    Shibaki, Ryota
    Shimizu, Toshio
    Kondo, Shunsuke
    Iwasa, Satoru
    Koyama, Takafumi
    Kitano, Shigehisa
    Sato, Jun
    Shimomura, Akihiko
    Suri, Ajit
    Kase, Yoichi
    Sumino, Shuuji
    Tamura, Kenji
    Yamamoto, Noboru
    Yonemori, Kan
    ANNALS OF ONCOLOGY, 2019, 30
  • [49] A phase I study of resminostat in Japanese patients with advanced solid tumors
    Kitazono, Satoru
    Fujiwara, Yutaka
    Nakamichi, Shinji
    Mizugaki, Hidenori
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Yamada, Yasuhide
    Inukai, Eri
    Nakamura, Osamu
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (06) : 1155 - 1161
  • [50] Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors (vol 17, pg 861, 2020)
    Taylor, Matthew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (23) : 2702 - 2702
12345